| Sanofi-Aventis (Suisse) SA - Vaxigrip, suspension injectable | | 70051 | | 02 | | Vaxigrip | | suspension injectable | | J07BB02 | | Influenza, Inactivated, Split Virus Or Surface Antigen | | 27.08.2025 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus souche A/Victoria/4897/2022 (H1N1)pdm09-like: reassortant virus IVR-238 derived from A/Victoria/4897/2022) 15 µg, haemagglutininum influenzae A (H3N2) (Virus souche A/Croatia/10136RV/2023 (H3N2)-like: reassortant virus X-425A derived from A/Croatia/10136RV/2023) 15 µg, haemagglutininum influenzae B (Virus souche B/Austria/1359417/2021-like: B/Michigan/01/2021, wilde type (Victoria lineage)) 15 µg, natrii chloridum, kalii chloridum, dinatrii phosphas dihydricus, kalii dihydrogenophosphas, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.72 mg, kalium 0.08 mg, residui: formaldehydum, octoxinolum-9, ovalbuminum, neomycinum. | | Packungsbestandteile | | | | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 003 | | 9.58 | 26.85 | B | SL | No | | 004 | 10 | | | B | | Yes |
|
|
